HUTCHMED (NASDAQ:HCM) Lowered to “Hold” Rating by StockNews.com

StockNews.com downgraded shares of HUTCHMED (NASDAQ:HCM) from a buy rating to a hold rating in a research note published on Monday.

Separately, The Goldman Sachs Group upped their target price on HUTCHMED from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Thursday, August 1st.

HUTCHMED Price Performance

NASDAQ HCM opened at $16.83 on Monday. HUTCHMED has a 12-month low of $11.93 and a 12-month high of $21.92. The firm’s fifty day simple moving average is $18.71 and its two-hundred day simple moving average is $18.65. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in HCM. Public Employees Retirement System of Ohio purchased a new stake in HUTCHMED in the third quarter valued at approximately $35,000. Blue Trust Inc. boosted its holdings in shares of HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock valued at $69,000 after acquiring an additional 3,057 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of HUTCHMED by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock worth $117,000 after acquiring an additional 2,321 shares during the period. Rhumbline Advisers raised its holdings in shares of HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock worth $129,000 after purchasing an additional 564 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in HUTCHMED during the second quarter valued at $213,000. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.